Pharmaceutical Information |
Drug Name |
Ofev |
Drug ID |
BADD_D01597 |
Description |
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014.[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.[A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459] |
Indications and Usage |
Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). |
Marketing Status |
Prescription |
ATC Code |
L01EX09 |
DrugBank ID |
DB09079
|
KEGG ID |
D10396
|
MeSH ID |
C530716
|
PubChem ID |
135423438
|
TTD Drug ID |
D09HNV
|
NDC Product Code |
55361-0020; 0597-0145; 55361-0021; 66499-0061; 0597-0143 |
Synonyms |
nintedanib | Nintedanib esylate | Ofev | Vargatef | BIBF 1120 | BIBF1120 | BIBF-1120 |
|
Chemical Information |
Molecular Formula |
C31H33N5O4 |
CAS Registry Number |
656247-17-5 |
SMILES |
CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
|